Anders Kverneland

874 total citations
19 papers, 573 citations indexed

About

Anders Kverneland is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Anders Kverneland has authored 19 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Immunology and 7 papers in Molecular Biology. Recurrent topics in Anders Kverneland's work include Cancer Immunotherapy and Biomarkers (10 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (7 papers). Anders Kverneland is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (7 papers). Anders Kverneland collaborates with scholars based in Denmark, Sweden and Germany. Anders Kverneland's co-authors include Inge Marie Svane, Marco Donia, Özcan Met, James A. Hutchinson, Mathias Streitz, Stephan Schlickeiser, Edward K. Geissler, Katrin Vogt, Birgit Sawitzki and Troels Holz Borch and has published in prestigious journals such as Nature Communications, Cancer Research and Scientific Reports.

In The Last Decade

Anders Kverneland

17 papers receiving 564 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anders Kverneland Denmark	11	321	290	134	56	47	19	573
Ahmed Shalabi United States	5	584 1.8×	450 1.6×	83 0.6×	55 1.0×	30 0.6×	6	783
Linghua Zheng United States	8	528 1.6×	411 1.4×	91 0.7×	25 0.4×	10 0.2×	13	713
Christine Appelt Germany	13	230 0.7×	86 0.3×	138 1.0×	47 0.8×	49 1.0×	17	504
Natalie Zimmerman United States	4	567 1.8×	282 1.0×	86 0.6×	50 0.9×	10 0.2×	4	736
Lucie Leveque Australia	12	635 2.0×	127 0.4×	104 0.8×	40 0.7×	27 0.6×	20	789
Katrin Baumann Finland	6	488 1.5×	99 0.3×	164 1.2×	27 0.5×	33 0.7×	7	672
Daniel Fürst Germany	14	551 1.7×	204 0.7×	124 0.9×	45 0.8×	101 2.1×	36	801
Carla M. van Herpen Netherlands	14	113 0.4×	325 1.1×	195 1.5×	98 1.8×	12 0.3×	27	608
Ryan Flynn United States	14	459 1.4×	145 0.5×	104 0.8×	48 0.9×	31 0.7×	20	692
Robert Sanchez Rodriguez United States	6	379 1.2×	416 1.4×	104 0.8×	40 0.7×	5 0.1×	10	607

Countries citing papers authored by Anders Kverneland

Since Specialization

Citations

This map shows the geographic impact of Anders Kverneland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Kverneland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Kverneland more than expected).

Fields of papers citing papers by Anders Kverneland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anders Kverneland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Kverneland. The network helps show where Anders Kverneland may publish in the future.

Co-authorship network of co-authors of Anders Kverneland

This figure shows the co-authorship network connecting the top 25 collaborators of Anders Kverneland. A scholar is included among the top collaborators of Anders Kverneland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anders Kverneland. Anders Kverneland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Martinenaite, Evelina, Cathrine Lund Lorentzen, Julie Westerlin Kjeldsen, et al.. (2025). Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma. Nature Communications. 17(1). 806–806.

Secci, Daniela, et al.. (2025). Dynamics of checkpoint receptors in γδ T cell subsets are associated with clinical response during anti-PD-1 immunotherapies. EMBO Molecular Medicine. 18(1). 91–119.

Kverneland, Anders, Florian Harking, Dorte B. Bekker‐Jensen, et al.. (2024). Fully Automated Workflow for Integrated Sample Digestion and Evotip Loading Enabling High-Throughput Clinical Proteomics. Molecular & Cellular Proteomics. 23(7). 100790–100790. 10 indexed citations

Franciosa, Giulia, et al.. (2023). Proteomics to study cancer immunity and improve treatment. Seminars in Immunopathology. 45(2). 241–251. 10 indexed citations

Kverneland, Anders, et al.. (2023). Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma. Immuno-Oncology Technology. 20. 100396–100396. 3 indexed citations

Chamberlain, Christopher A., Eric Bennett, Anders Kverneland, et al.. (2022). Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. Molecular Therapy — Oncolytics. 24. 417–428. 50 indexed citations

Kverneland, Anders, Ole Østergaard, Kristina B. Emdal, Inge Marie Svane, & Jesper V. Olsen. (2022). Differential ultracentrifugation enables deep plasma proteomics through enrichment of extracellular vesicles. PROTEOMICS. 23(7-8). e2200039–e2200039. 19 indexed citations

Kverneland, Anders, Christopher A. Chamberlain, Troels Holz Borch, et al.. (2021). Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. Journal for ImmunoTherapy of Cancer. 9(10). e003499–e003499. 45 indexed citations

Borch, Troels Holz, Katja Harbst, Rikke Andersen, et al.. (2021). Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. Journal for ImmunoTherapy of Cancer. 9(7). e002703–e002703. 21 indexed citations

10.

Draghi, Arianna, Christopher A. Chamberlain, Shawez Khan, et al.. (2021). Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens. Frontiers in Immunology. 12. 705422–705422. 14 indexed citations

11.

Kverneland, Anders, Troels Holz Borch, Joachim Stoltenborg Granhøj, et al.. (2021). Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition. Cytotherapy. 23(8). 724–729. 4 indexed citations

12.

Jensen, Christina, Anders Kverneland, Marco Donia, et al.. (2021). Abstract 386: Evaluation of CPa9-HNE - a peripheral biomarker based on neutrophil extracellular traps (NETs) - for predicting outcome in patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Research. 81(13_Supplement). 386–386. 2 indexed citations

13.

Harbst, Katja, Troels Holz Borch, Marie Christine Wulff Westergaard, et al.. (2020). CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer. Scientific Reports. 10(1). 3914–3914. 50 indexed citations

14.

Kverneland, Anders, Troels Holz Borch, Christopher A. Chamberlain, et al.. (2020). 1022MO Clinical potential of adoptive cell therapy with tumour infiltrating lymphocytes therapy in combination with checkpoint inhibitors in non-melanoma patients. Annals of Oncology. 31. S706–S706. 1 indexed citations

15.

Kverneland, Anders, Magnus Pedersen, Marie Christine Wulff Westergaard, et al.. (2020). Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. Oncotarget. 11(22). 2092–2105. 77 indexed citations

16.

Kverneland, Anders, Christian Enevold, Marco Donia, et al.. (2018). Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. OncoImmunology. 7(5). e1424674–e1424674. 48 indexed citations

17.

Borch, Troels Holz, Per Kongsted, Magnus Pedersen, et al.. (2018). Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor induction in checkpoint inhibitor resistant metastatic melanoma patients. Annals of Oncology. 29. viii402–viii402. 2 indexed citations

18.

Kverneland, Anders, Mathias Streitz, Edward K. Geissler, et al.. (2016). Age and gender leucocytes variances and references values generated using the standardized ONE‐Study protocol. Cytometry Part A. 89(6). 543–564. 64 indexed citations

19.

Streitz, Mathias, Tewfik Miloud, Michael Kapinsky, et al.. (2013). Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. PubMed. 2(1). 17–17. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact